Advanced

Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.

Nilsson, Jan LU ; Nordin Fredrikson, Gunilla LU ; Schiopu, Alexandru LU ; Shah, Prediman K; Jansson, Bo LU and Carlsson, Roland LU (2007) In Current Pharmaceutical Design 13(10). p.1021-1030
Abstract
Immune responses against oxidized forms of LDL play a critical role in activation and regulation of the inflammatory process that characterizes all stages of atherosclerosis. In humans oxidized LDL is targeted by both IgM and IgG autoantibodies. Immunization of hypercholesterolemic animals with oxidized LDL has been shown to inhibit atherosclerosis demonstrating that at least some of these immune responses have a protective effect. The identification of the structures in oxidized LDL that are responsible for activation of immunity has made it possible to develop novel therapeutic approaches for treatment of atherosclerosis based on active (vaccines) and passive (antibodies) immunization. Studies performed in atherosclerosis-prone mice... (More)
Immune responses against oxidized forms of LDL play a critical role in activation and regulation of the inflammatory process that characterizes all stages of atherosclerosis. In humans oxidized LDL is targeted by both IgM and IgG autoantibodies. Immunization of hypercholesterolemic animals with oxidized LDL has been shown to inhibit atherosclerosis demonstrating that at least some of these immune responses have a protective effect. The identification of the structures in oxidized LDL that are responsible for activation of immunity has made it possible to develop novel therapeutic approaches for treatment of atherosclerosis based on active (vaccines) and passive (antibodies) immunization. Studies performed in atherosclerosis-prone mice demonstrate that both peptide-based vaccines and recombinant IgG targeting epitopes in oxidized LDL significantly reduce atherosclerosis. There is also evidence antibodies against oxidized LDL could also be used for imaging atherosclerosis. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Current Pharmaceutical Design
volume
13
issue
10
pages
1021 - 1030
publisher
Bentham Science Publishers
external identifiers
  • wos:000246498700006
  • scopus:34247874714
ISSN
1381-6128
DOI
10.2174/138161207780487557
language
English
LU publication?
yes
id
379a5d99-3c62-4c2f-8a9d-a6f43ab2cb31 (old id 167667)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17430165&dopt=Abstract
date added to LUP
2007-07-23 16:35:18
date last changed
2017-09-10 03:48:33
@article{379a5d99-3c62-4c2f-8a9d-a6f43ab2cb31,
  abstract     = {Immune responses against oxidized forms of LDL play a critical role in activation and regulation of the inflammatory process that characterizes all stages of atherosclerosis. In humans oxidized LDL is targeted by both IgM and IgG autoantibodies. Immunization of hypercholesterolemic animals with oxidized LDL has been shown to inhibit atherosclerosis demonstrating that at least some of these immune responses have a protective effect. The identification of the structures in oxidized LDL that are responsible for activation of immunity has made it possible to develop novel therapeutic approaches for treatment of atherosclerosis based on active (vaccines) and passive (antibodies) immunization. Studies performed in atherosclerosis-prone mice demonstrate that both peptide-based vaccines and recombinant IgG targeting epitopes in oxidized LDL significantly reduce atherosclerosis. There is also evidence antibodies against oxidized LDL could also be used for imaging atherosclerosis.},
  author       = {Nilsson, Jan and Nordin Fredrikson, Gunilla and Schiopu, Alexandru and Shah, Prediman K and Jansson, Bo and Carlsson, Roland},
  issn         = {1381-6128},
  language     = {eng},
  number       = {10},
  pages        = {1021--1030},
  publisher    = {Bentham Science Publishers},
  series       = {Current Pharmaceutical Design},
  title        = {Oxidized LDL antibodies in treatment and risk assessment of atherosclerosis and associated cardiovascular disease.},
  url          = {http://dx.doi.org/10.2174/138161207780487557},
  volume       = {13},
  year         = {2007},
}